1.
Comparison of Expected Versus Actual Cost Consequence Of Reimbursed Drugs in the Netherlands Between 2009 and 2013
2.
Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands